

1642  
PATENT

Attorney Docket No. UCSD-07017

P#8

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Maurizio Zanetti

Serial No.: 09/788,110

Group No.: Not yet assigned

Filed: 02/15/2001

Examiner: Not yet assigned

Entitled: **A Universal Vaccine and Method for Treating  
Cancer Employing Telomerase Reverse  
Transcriptase****TRANSMITTAL FOR  
INFORMATION DISCLOSURE STATEMENT**Assistant Commissioner for Patents  
Washington, D.C. 20231**RECEIVED**

DEC 03 2002

TECH CENTER 1800/2900

**CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on November 27, 2002.

By: 

Cliff Cannon-Cin


Sir or Madam:


Enclosed please find an Information Disclosure Statement, Form PTO-1449 and copy of 68 references for filing in the U.S. Patent and Trademark Office.

In the event a petition is required in order to have this Information Disclosure Statement considered, please consider this a petition therefor.

The Commissioner is hereby authorized to charge any fee or credit overpayment related to this filing to our Deposit Account No. **08-1290**. **An originally executed duplicate of this transmittal is enclosed for this purpose.**

Signed on behalf of:

Dated: 11/27/2002  
Maha A. Hamdan  
Registration No. 43,655MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94105  
415.904.6500



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Maurizio Zanetti

Serial No.: 09/788,110

Filed: 02/15/2001

Entitled: **A Universal Vaccine and Method for Treating  
Cancer Employing Telomerase Reverse  
Transcriptase**

Group No.: Not yet assigned

Examiner: Not yet assigned

INFORMATION DISCLOSURE STATEMENT

RECEIVED

DEC 03 2002

Assistant Commissioner for Patents  
Washington, D.C. 20231

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on  
November 27, 2002

By

  
Cliff Cannon-Cin

Sir or Madam:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

The following patents are referred to in the body of the specification:

- US Patent No. 4,622,952 issued 11/18/86 to Gordon;
- US Patent No. 5,658,234 issued 8/19/97 to Dunlavy;
- US Patent No. 6,106,829 issued 8/22/00 to He *et al.*;

The following publications are referred to in the body of the specification:

- Mattes *et al.* (1983) "A Pigmentation-associated, Differentiation Antigen of Human Melanoma Defined by a Precipitating Antibody in Human Serum," Int. J. Cancer 32:717;
- Tai *et al.* (1983) "Glycoproteins as Differentiation Markers in Human Malignant Melanoma and Melanocytes," Cancer Res. 43:2773;

- Thomson *et al.* (1988) "Differentiation Antigens of Melanocytes and Melanoma: Analysis of Melanosome and Cell Surface Markers of Human Pigmented Cells with Monoclonal Antibodies," J. Invest. Dermatol. 90:459;
- Zakian (1995) "Telomeres: Beginning to Understand the End," Science 270:1601;
- Blackburn and Gall (1978) "A Tandemly Repeated Sequence at the Termini of the Extrachromosomal Ribosomal RNA Genes in *Tetrahymena*," J. Mol. Biol. 120:33;
- Oka *et al.* (1980) "Inverted terminal repeat sequence in the macronuclear DNA of *Stylonychia pustulata*," Gene 10:301;
- Klobutcher *et al.* (1981) "All gene-sized DNA molecules in four species of hypotrichs have the same terminal sequence and an unusual 3' terminus," Proc. Natl. Acad. Sci. 78:3015; and
- Wellinger *et al.* (1993) "Origin Activation and Formation of Single-Strand TG<sub>1-3</sub> Tails Occur Sequentially in Late S Phase on a Yeast Linear Plasmid," Mol. Cell. Biol. 13:4057.

Applicants have become aware of the following printed publication which may be material to the examination of this application and which are listed in alphabetical order:

- US Patent No. 5,635,188 issued 6/3/97 to Bystryn;
- US Patent No. 6,168,946 issued 1/2/01 to Houghton *et al.*;
- Minev *et al.* (2000) "Cytotoxic T cell immunity against telomerase reverse transcriptase in humans," Proc. Natl. Acad. Sci. USA 97:4796-4801;
- Vonderheide *et al.* (1999) "The Telomerase Catalytic Subunit Is a Widely Expressed Tumor-Associated Antigen Recognized by Cytotoxic T Lymphocytes," Immunity 10:673-679;
- Blackburn (1992) "Telomerases," Ann. Rev. Biochem. 61:1139-129;
- Blackburn (1991) "Structure and function of telomeres," Nature 350:569-73;
- Greider (1994) "Mammalian telomere dynamics: healing, fragmentation shortening and stabilization," Curr. Opin. Genet. Devel. 4:203-11;

- Counter *et al.* (1992) "Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity," EMBO J. 11:1921-29;
- Buchkovich *et al.* (1996) "Telomerase Regulation during Entry into the Cell Cycle in Normal Human T Cells," Mol. Biol. Cell 7:1443-54;
- Weng *et al.* (1996) "Regulated Expression of Telomerase Activity in Human T Lymphocyte Development and Activation," J. Exp. Med. 183:2471-9;
- Weng *et al.* (1997) "Telomere lengthening and telomerase activation during human B cell differentiation," Proc. Natl. Acad. Sci. USA 94:10827-32;
- Lee *et al.* (1998) "Essential role of mouse telomerase in highly proliferative organs," Nature 392:569-74;
- Kim *et al.* (1994) "Specific Association of Human Telomerase Activity with Immortal Cells and Cancer," Science 266:2011-5;
- Meyerson *et al.* (1997) "hEST2, the Putative Human Telomerase Catalytic Subunit Gene, is Up-Regulated in Tumor Cells and during Immortalization," Cell 90:785-795;
- Bodnar *et al.* (1998) "Extension of Life-Span by Introduction of Telomerase into Normal Human Cells," Science 279:349-52;
- Rudolph *et al.* (1999) "Longevity, Stress Response, and Cancer in Aging Telomerase-Deficient Mice," Cell 96:701-12;
- Greenberg *et al.* (1999) "Short Dysfunctional Telomeres Impair Tumorigenesis in the INK4a<sup>Δ2/3</sup> Cancer-Prone Mouse," Cell 97:515-25;
- Morales *et al.* (1999) "Absence of cancer-associated changes in human fibroblasts immortalized with telomerase," Nature Genetics 21:115-8;
- Hahn *et al.* (1999) "Creation of human tumour cells with defined genetic elements," Nature 400:464-8;
- Broccoli *et al.* (1995) "Telomerase activity in normal and malignant hematopoietic cells," Proc. Natl. Acad. Sci. USA 92:9082-6;
- Shay *et al.* (1997) "A Survey of Telomerase Activity in Human Cancer," Eur. J. Cancer 33:787-91;

- Kim (1997) "Clinical Implications of Telomerase in Cancer," *Eur. J. Cancer* 33:-781-6;
- Nakamura *et al.* (1997) "Telomerase Catalytic Subunit Homologs from Fission Yeast and Human," *Science* 277:955-9;
- Marx (1993) "How p53 Suppresses Cell Growth." *Science* 262:1644-5;
- Disis *et al.* (1997) "HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer," *Adv. Cancer Res.* 71:343-71;
- Walker *et al.* (1988) "HIV-1 Reverse Transcriptase Is a Target for Cytotoxic T Lymphocytes in Infected Individuals," *Science* 240:64-6;
- Schwartz (1990) "A Cell Culture Model for T Lymphocyte Clonal Anergy," *Science* 248:1349-56;
- Firat *et al.* (1999) "H-2 class I knockout, HLA-12.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies," *Eur. J. Immunol.* 29:3112-21;
- Lee (1990) in *The HLA System*, ed. Lee, J. (Springer-Verlag, NY), pp 141-178;
- Fernandez-Vina *et al.* (1992) "DNA Typing for HLA Class I Alleles: I. Subsets of HLA-A2 and of -A28," *Human Immunol.* 33:163-73;
- Krausa *et al.* (1995) "Genetic polymorphism within HLA-A\*02: significant allelic variation revealed in different populations," *Tissue Antigens* 45:223-31;
- Ruppert *et al.* (1993) "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules," *Cell.* 74:929-37;
- Parker *et al.* (1994) "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," *J. Immunol.* 152:163-75;
- Vitiello *et al.* (1991) "Analysis of the HLA-restricted Influenza-specific Cytotoxic T Lymphocyte Response in Transgenic Mice Carrying a Chimeric Human-Mouse Class I Major Histocompatibility Complex," *J. Exp. Med.* 173:1007-15;
- Sette *et al.* (1994) "The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes," *J. Immunol.* 153:5586-92;

- van der Burg *et al.* (1996) "Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stability," J. Immunol. 156:3308-14;
- Sommerfeld *et al.* (1996) "Telomerase Activity: A Prevalent Marker of Malignant Human Prostate Tissue," Cancer Res. 56:218-22;
- Hunt *et al.* (1992) "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry," Science 1261-3;
- Quaranta *et al.* (1982) "A Recurrent Idiotype on Monoclonal Anti-Human Ia Antibodies," J. Exp. Med. 156:1551-6;
- Zanetti *et al.* (1993) "Expression of conformationally constrained adhesion peptide in an antibody CDR loop and inhibition of natural killer cell cytotoxic activity by an antibody antigenized with the RGD motif," EMBO J. 12:4375-4384;
- Hiyama *et al.* (1995) "Activation of Telomerase in Human Lymphocytes and Hematopoietic Progenitor Cells," J. Immunol. 155:3711-15;
- Pascolo *et al.* (1997) "HLA-A2.1-restricted Education and Cytolytic Activity of CD8<sup>+</sup> T Lymphocytes from  $\beta$ 2 Microglobulin ( $\beta$ 2m) HLA-A2.1 Monochain Transgenic H-2D<sup>b</sup>  $\beta$ 2m Double Knockout Mice," J. Exp. Med. 185:2043-51;
- Doyle *et al.* (1985) "Markedly Decreased Expression of Class I Histocompatibility Antigens, Protein, and mRNA in Human Small-Cell Lung Cancer," J. Exp. Med. 161:1135-51;
- Momburg *et al.* (1986) "Loss of HLA-A,B,C and *De Novo* Expression of HLA-D in Colorectal Cancer," Int. J. Cancer 37:179-84;
- Restifo *et al.* (1993) "Identification of Human Cancers Deficient in Antigen Processing," J. Exp. Med. 177:265-72;
- Cromme *et al.* (1994) "Loss of Transporter Protein, Encoded by the TAP-1 Gene, is Highly Correlated with Loss of HLA Expression in Cervical Carcinomas," J. Exp. Med. 179:335-40;
- Rosenberg *et al.* (1998) "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma," Nature Med. 4:321-27;

- Nestle *et al.* (1998) "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells," *Nature Med.* 4:328-332;
- Thomson *et al.* (1998) "Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination," *J. Immunol.* 160:1717-23;
- Sykulev *et al.* (1996) "Evidence that a Single Peptide-MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response," *Immunity* 4:565-71;
- Morgan *et al.* (1998) "Activation of Low Avidity CTL Specific for a Self Epitope Results in Tumor Rejection But Not Autoimmunity," *J. Immunol.* 160:643-51;
- Overwijk *et al.* (1999) "Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4<sup>+</sup> T lymphocytes," *Proc. Natl. Acad. Sci. USA* 96:2982-7;
- Hu *et al.* (1993) "An Evaluation of the Potential to Use Tumor-associated Antigens as Targets for Antitumor T Cell Therapy Using Transgenic Mice Expressing a Retroviral Tumor Antigen in Normal Lymphoid Tissues," *J. Exp. Med.* 177:1681-90;
- Uyttenhove *et al.* (1997) "The Expression of Mouse Gene *P1A* In Testis Does Not Prevent Safe Induction of Cytolytic T Cells Against a P1A-Encoded Tumor Antigen," *Int. J. Cancer* 70:349-56;
- Falk *et al.* (1991) "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," *Nature* 351:290-6;
- Rotzschke *et al.* (1990) "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells," *Nature* 348:252-254; and
- Schumacher *et al.* (1991) "Peptide selection by MHC class I molecules," *Nature* 350:703-6.

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Signed on behalf of:

Dated: November 27, 2002

A handwritten signature in dark ink, appearing to read "Maha Hamdan", is written over a horizontal line.

Maha A. Hamdan  
Registration No. 43,655

MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94105  
415.904.6500



FORM PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.: UCSD-07017

Serial No.: 09/788,110

INFORMATION DISCLOSURE STATEMENT BY APPLICANT  
(Use Several Sheets If Necessary)

Applicant: Maurizio Zanetti

Filing Date: 02/15/01

Group Art Unit:

(37 CFR § 1.98(b))

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
	1	4,622,952	11/18/86	Gordon			
	2	5,658,234	8/19/97	Dunlavy			
	3	6,106,829	8/22/00	He <i>et al.</i>			
	4	6,168,946	1/2/01	Houghton <i>et al.</i>			
	5	5,635,188	6/3/97	Bystryn			

## OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

6	✓	Mattes <i>et al.</i> (1983) "A Pigmentation-associated, Differentiation Antigen of Human Melanoma Defined by a Precipitating Antibody in Human Serum," <i>Int. J. Cancer</i> 32:717
7	✓	Tai <i>et al.</i> (1983) "Glycoproteins as Differentiation Markers in Human Malignant Melanoma and Melanocytes," <i>Cancer Res.</i> 43:2773
8	✓	Thomson <i>et al.</i> (1988) "Differentiation Antigens of Melanocytes and Melanoma: Analysis of Melanosome and Cell Surface Markers of Human Pigmented Cells with Monoclonal Antibodies," <i>J. Invest. Dermatol.</i> 90:459
9	✓	Zakian (1995) "Telomeres: Beginning to Understand the End," <i>Science</i> 270:1601
10	✓	Blackburn and Gall (1978) "A Tandemly Repeated Sequence at the Termini of the Extrachromosomal Ribosomal RNA Genes in <i>Tetrahymena</i> ," <i>J. Mol. Biol.</i> 120:33
11	✓	Oka <i>et al.</i> (1980) "Inverted terminal repeat sequence in the macronuclear DNA of <i>Stylonychia pustulata</i> ," <i>Gene</i> 10:301
12	✓	Klobutcher <i>et al.</i> (1981) "All gene-sized DNA molecules in four species of hypotrichs have the same terminal sequence and an unusual 3' terminus," <i>Proc. Natl. Acad. Sci.</i> 78:3015
13	✓	Wellinger <i>et al.</i> (1993) "Origin Activation and Formation of Single-Strand TG <sub>1-3</sub> Tails Occur Sequentially in Late S Phase on a Yeast Linear Plasmid," <i>Mol. Cell. Biol.</i> 13:4057
14	✓	Minev <i>et al.</i> (2000) "Cytotoxic T cell immunity against telomerase reverse transcriptase in humans," <i>Proc. Natl. Acad. Sci. USA</i> 97:4796-4801
15	✓	Vonderheide <i>et al.</i> (1999) "The Telomerase Catalytic Subunit Is a Widely Expressed Tumor-Associated Antigen Recognized by Cytotoxic T Lymphocytes," <i>Immunity</i> 10:673-679
16	✓	Blackburn (1992) "Telomerases," <i>Ann. Rev. Biochem.</i> 61:1139-129
17	✓	Blackburn (1991) "Structure and function of telomeres," <i>Nature</i> 350:569-73
18	✓	Greider (1994) "Mammalian telomere dynamics: healing, fragmentation shortening and stabilization," <i>Curr. Opin. Genet. Devel.</i> 4:203-11
19	✓	Counter <i>et al.</i> (1992) "Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity," <i>EMBO J.</i> 11:1921-29
20	✓	Buchkovich <i>et al.</i> (1996) "Telomerase Regulation during Entry into the Cell Cycle in Normal Human T Cells," <i>Mol. Biol. Cell</i> 7:1443-54
21	✓	Weng <i>et al.</i> (1996) "Regulated Expression of Telomerase Activity in Human T Lymphocyte Development and Activation," <i>J. Exp. Med.</i> 183:2471-9
22	✓	Weng <i>et al.</i> (1997) "Telomere lengthening and telomerase activation during human B cell differentiation," <i>Proc. Natl. Acad. Sci. USA</i> 94:10827-32
23	✓	Lee <i>et al.</i> (1998) "Essential role of mouse telomerase in highly proliferative organs," <i>Nature</i> 392:569-74
24	✓	Kim <i>et al.</i> (1994) "Specific Association of Human Telomerase Activity with Immortal Cells and Cancer," <i>Science</i> 266:2011-5
25	✓	Meyerson <i>et al.</i> (1997) "hEST2, the Putative Human Telomerase Catalytic Subunit Gene, is Up-Regulated in Tumor Cells and during Immortalization," <i>Cell</i> 90:785-795

Examiner:

Date Considered:

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.: UCSD-02424

Serial No.: 08/723,052

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**  
(Use Several Sheets If Necessary)Applicant: Mario Chojkier *et al.*

(37 CFR § 1.98(b))

Filing Date: 09/30/96

Group Art Unit:

**OTHER DOCUMENTS** (Including Author, Title, Date, Relevant Pages, Place of Publication)

- |    |  |
|----|--|
| 26 | Bodnar <i>et al.</i> (1998) "Extension of Life-Span by Introduction of Telomerase into Normal Human Cells," Science 279:349-52   |
| 27 | Rudolph <i>et al.</i> (1999) "Longevity, Stress Response, and Cancer in Aging Telomerase-Deficient Mice," Cell 96:701-12   |
| 28 | Greenberg <i>et al.</i> (1999) "Short Dysfunctional Telomeres Impair Tumorigenesis in the INK4a <sup>Δ2/3</sup> Cancer-Prone Mouse," Cell 97:515-25  |
| 29 | Morales <i>et al.</i> (1999) "Absence of cancer-associated changes in human fibroblasts immortalized with telomerase," Nature Genetics 21:115-8  |
| 30 | Hahn <i>et al.</i> (1999) "Creation of human tumour cells with defined genetic elements," Nature 400:464-8   |
| 31 | Broccoli <i>et al.</i> (1995) "Telomerase activity in normal and malignant hematopoietic cells," Proc. Natl. Acad. Sci. USA 92:9982-6  |
| 32 | Shay <i>et al.</i> (1997) "A Survey of Telomerase Activity in Human Cancer," Eur. J. Cancer 33:787-91  |
| 33 | Kim (1997) "Clinical Implications of Telomerase in Cancer," Eur. J. Cancer 33:781-6  |
| 34 | Nakamura <i>et al.</i> (1997) "Telomerase Catalytic Subunit Homologs from Fission Yeast and Human," Science 277:955-9  |
| 35 | Marx (1993) "How p53 Suppresses Cell Growth," Science 262:1644-5   |
| 36 | Disis <i>et al.</i> (1997) "HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer," Adv. Cancer Res. 71:343-71  |
| 37 | Walker <i>et al.</i> (1988) "HIV-1 Reverse Transcriptase Is a Target for Cytotoxic T Lymphocytes in Infected Individuals," Science 240:64-6  |
| 38 | Schwartz (1990) "A Cell Culture Model for T Lymphocyte Clonal Anergy," Science 248:1349-56   |
| 39 | Firat <i>et al.</i> (1999) "H-2 class I knockout, HLA-12.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies," Eur. J. Immunol. 29:3112-21  |
| 40 | Lee (1990) in <i>The HLA System</i> , ed. Lee, J. (Springer-Verlag, NY), pp 141-178  |
| 41 | Fernandez-Vina <i>et al.</i> (1992) "DNA Typing for HLA Class I Alleles, I. Subsets of HLA-A2 and of -A28," Human Immunol. 33:163-73   |
| 42 | Krausa <i>et al.</i> (1995) "Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations," Tissue Antigens 45:223-31;  |
| 43 | Ruppert <i>et al.</i> (1993) "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules," Cell. 74:929-37;  |
| 44 | Parker <i>et al.</i> (1994) "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," J. Immunol. 152:163-75  |
| 45 | Vitiello <i>et al.</i> (1991) "Analysis of the HLA-restricted Influenza-specific Cytotoxic T Lymphocyte Response in Transgenic Mice Carrying a Chimeric Human-Mouse Class I Major Histocompatibility Complex," J. Exp. Med. 173:1007-15              |
| 46 | Sette <i>et al.</i> (1994) "The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes," J. Immunol. 153:5586-92  |
| 47 | van der Burg <i>et al.</i> (1996) "Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stability," J. Immunol. 156:3308-14  |
| 48 | Sommerfeld <i>et al.</i> (1996) "Telomerase Activity: A Prevalent Marker of Malignant Human Prostate Tissue," Cancer Res. 56:218-22  |
| 49 | Hunt <i>et al.</i> (1992) "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry," Science 257:1261-3   |
| 50 | Quaranta <i>et al.</i> (1982) "A Recurrent Idiotypic on Monoclonal Anti-Human Ia Antibodies," J. Exp. Med. 156:1551-6  |
| 51 | Zanetti <i>et al.</i> (1993) "Expression of conformationally constrained adhesion peptide in an antibody CDR loop and inhibition of natural killer cell cytotoxic activity by an antibody antigenized with the RGD motif," EMBO J. 12:4375-4384      |
| 52 | Hiyama <i>et al.</i> (1995) "Activation of Telomerase in Human Lymphocytes and Hematopoietic Progenitor Cells," J. Immunol. 155:3711-15  |
| 53 | Pascolo <i>et al.</i> (1997) "HLA-A2.1-restricted Education and Cytolytic Activity of CD8 <sup>+</sup> T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2D <sup>b</sup> β2m Double Knockout Mice," J. Exp. Med. 185:2043-51 |
| 54 | Doyle <i>et al.</i> (1985) "Markedly Decreased Expression of Class I Histocompatibility Antigens, Protein, and mRNA in Human Small-Cell Lung Cancer," J. Exp. Med. 161:1135-51   |

Examiner:

Date Considered:

**EXAMINER:**

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UCSD-02424	Serial No.: 08/723,052
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: Mario Chojkier <i>et al.</i>	
				Filing Date: 09/30/96	Group Art Unit:
(37 CFR § 1.98(b))					
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
	55	/	Momburg <i>et al.</i> (1986) "Loss of HLA-A,B,C and <i>De Novo</i> Expression of HLA-D in Colorectal Cancer," Int. J. Cancer 37:179-84	<div style="text-align: center;"> <b>RECEIVED</b>  <b>DEC 03 2002</b>  <b>TECH CENTER 1800/2900</b> </div>	
	56	/	Restifo <i>et al.</i> (1993) "Identification of Human Cancers Deficient in Antigen Processing," J. Exp. Med. 177:365-71		
	57	/	Cromme <i>et al.</i> (1994) "Loss of Transporter Protein, Encoded by the TAP-1 Gene, is Highly Correlated with Loss of HLA Expression in Cervical Carcinomas," J. Exp. Med. 179:335-40		
	58	/	Rosenberg <i>et al.</i> (1998) "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with melanoma," Nature Med. 4:321-27		
	59	/	Nestle <i>et al.</i> (1998) "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells," Nature Med. 4:328-332		
	60	/	Thomson <i>et al.</i> (1998) "Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination," J. Immunol. 160:1717-23		
	61	/	Sykulev <i>et al.</i> (1996) "Evidence that a Single Peptide-MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response," Immunity 4:565-71		
	62	/	Morgan <i>et al.</i> (1998) "Activation of Low Avidity CTL Specific for a Self Epitope Results in Tumor Rejection But Not Autoimmunity," J. Immunol. 160:643-51		
	63	/	Overwijk <i>et al.</i> (1999) "Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4 <sup>+</sup> T lymphocytes," Proc. Natl. Acad. Sci. USA 96:2982-7		
	64	/	Hu <i>et al.</i> (1993) "An Evaluation of the Potential to Use Tumor-associated Antigens as Targets for Antitumor T Cell Therapy Using Transgenic Mice Expressing a Retroviral Tumor Antigen in Normal Lymphoid Tissues," J. Exp. Med. 177:1681-90		
	65	/	Uyttenhove <i>et al.</i> (1997) "The Expression of Mouse Gene <i>PIA</i> In Testis Does Not Prevent Safe Induction of Cytolytic T Cells Against a <i>PIA</i> -Encoded Tumor Antigen," Int. J. Cancer 70:349-56		
	66	/	Falk <i>et al.</i> (1991) "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," Nature 351:290-6		
	67	/	Rotzschke <i>et al.</i> (1990) "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells," Nature 348:252-254		
	68	/	Schumacher <i>et al.</i> (1991) "Peptide selection by MHC class I molecules," Nature 350:703-6		
Examiner:				Date Considered:	
<b>EXAMINER:</b> Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

